|
|
|
|
During the 8 weeks of tetrathiomolybdate administration,only 1 of the 33 patients showed deterioration in neurologic function.Copper status and potential further toxic effects were generally well controlled quickly. Evaluation of data from individual patients revealed evidence of a toxic side effect in only 1 patient,who exhibited reversible anemia.During the ensuing period of follow-up of 1 to 6 years,neurologic recovery in most patients was good to excellent.Tetrathiomolybdate appears to be an excellent form of initial treatment in patients with Wilson disease who present with neurologic symptoms and signs.In contrast to penicillamine therapy,initial treatment with tetrathiomolybdate rarely allows further, often irreversible,neurologic deterioration. |
|